📊 BIO-B Key Takeaways
Is Bio-Rad Laboratories, Inc.. (BIO-B) a Good Investment?
Bio-Rad demonstrates exceptional profitability with a 29.4% net margin and strong balance sheet fundamentals, but growth stagnation (0% revenue YoY) and critically weak operating margin of 1.8% raise concerns about operational efficiency and sustainability. The dramatic 141% net income spike appears driven by non-operating items rather than core business improvement, warranting caution despite solid liquidity and cash generation.
Bio-Rad shows strong balance-sheet quality, ample liquidity, and solid free cash flow generation, which provide resilience and strategic flexibility. However, core operating performance looks weak given flat revenue, a 1.8% operating margin, and interest coverage of just 1.0x, while the surge in net income appears driven by non-core factors rather than underlying business improvement. The fundamentals support stability, but not a clearly strong growth or profitability profile at this stage.
Why Buy Bio-Rad Laboratories, Inc.. Stock? BIO-B Key Strengths
- Exceptional net profit margin of 29.4% indicating strong bottom-line profitability despite operational challenges
- Fortress balance sheet with debt/equity of 0.16x, current ratio of 5.62x, and substantial free cash flow of $374.6M
- Strong free cash flow generation of $374.6M ($14.5% FCF margin) provides financial flexibility and reinvestment capacity
- Very strong liquidity with a 5.62x current ratio and 4.19x quick ratio
- Low leverage with debt-to-equity of 0.16x and a large equity base
- Healthy cash generation with $374.6M of free cash flow and a 14.5% FCF margin
BIO-B Stock Risks: Bio-Rad Laboratories, Inc.. Investment Risks
- Flat year-over-year revenue growth of 0% signals stalled top-line expansion and potential market maturity or competitive pressures
- Dangerously low operating margin of 1.8% despite 51.9% gross margin suggests severe operational inefficiencies or cost structure problems
- Interest coverage ratio of 1.0x indicates minimal debt service cushion; net income surge appears anomalous (141% YoY) and likely unsustainable, suggesting one-time gains masking underlying weakness
- Revenue was flat year over year, indicating limited top-line momentum
- Operating profitability is weak with only a 1.8% operating margin
- Net income growth appears low quality relative to core operations, and interest coverage at 1.0x leaves little cushion
Key Metrics to Watch
- Revenue growth trajectory and segment performance to determine if 0% growth is temporary or structural
- Operating margin expansion and cost structure optimization to validate core business profitability
- Source of net income spike to assess sustainability and distinguish between operating improvements vs. one-time gains
- Operating margin improvement
- Organic revenue growth
Bio-Rad Laboratories, Inc.. (BIO-B) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.62x current ratio provides a solid financial cushion.
BIO-B Profit Margin, ROE & Profitability Analysis
BIO-B vs Industrial Sector: How Bio-Rad Laboratories, Inc.. Compares
How Bio-Rad Laboratories, Inc.. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bio-Rad Laboratories, Inc.. Stock Overvalued? BIO-B Valuation Analysis 2026
Based on fundamental analysis, Bio-Rad Laboratories, Inc.. appears fundamentally strong relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bio-Rad Laboratories, Inc.. Balance Sheet: BIO-B Debt, Cash & Liquidity
BIO-B Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bio-Rad Laboratories, Inc..'s revenue has remained relatively flat over the 5-year period, with a 9% decline. The most recent EPS of $-21.82 indicates the company is currently unprofitable.
BIO-B Revenue Growth, EPS Growth & YoY Performance
BIO-B Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $649.7M | $39.9M | $1.46 |
| Q2 2025 | $638.5M | $64.0M | $11.67 |
| Q1 2025 | $585.4M | $64.0M | $2.29 |
| Q3 2024 | $632.1M | $69.0M | $3.64 |
| Q2 2024 | $638.5M | $69.0M | $-37.09 |
| Q1 2024 | $610.8M | $69.0M | $2.32 |
| Q3 2023 | $632.1M | $69.0M | $3.64 |
| Q2 2023 | $681.1M | $69.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bio-Rad Laboratories, Inc.. Dividends, Buybacks & Capital Allocation
BIO-B SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bio-Rad Laboratories, Inc.. (CIK: 0000012208)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIO-B
What is the AI rating for BIO-B?
Bio-Rad Laboratories, Inc.. (BIO-B) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIO-B's key strengths?
Claude: Exceptional net profit margin of 29.4% indicating strong bottom-line profitability despite operational challenges. Fortress balance sheet with debt/equity of 0.16x, current ratio of 5.62x, and substantial free cash flow of $374.6M. ChatGPT: Very strong liquidity with a 5.62x current ratio and 4.19x quick ratio. Low leverage with debt-to-equity of 0.16x and a large equity base.
What are the risks of investing in BIO-B?
Claude: Flat year-over-year revenue growth of 0% signals stalled top-line expansion and potential market maturity or competitive pressures. Dangerously low operating margin of 1.8% despite 51.9% gross margin suggests severe operational inefficiencies or cost structure problems. ChatGPT: Revenue was flat year over year, indicating limited top-line momentum. Operating profitability is weak with only a 1.8% operating margin.
What is BIO-B's revenue and growth?
Bio-Rad Laboratories, Inc.. reported revenue of $2.6B.
Does BIO-B pay dividends?
Bio-Rad Laboratories, Inc.. does not currently pay dividends.
Where can I find BIO-B SEC filings?
Official SEC filings for Bio-Rad Laboratories, Inc.. (CIK: 0000012208) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIO-B's EPS?
Bio-Rad Laboratories, Inc.. has a diluted EPS of $27.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BIO-B a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bio-Rad Laboratories, Inc.. has a HOLD rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BIO-B stock overvalued or undervalued?
Valuation metrics for BIO-B: ROE of 10.2% (sector avg: 15%), net margin of 29.4% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BIO-B stock in 2026?
Our dual AI analysis gives Bio-Rad Laboratories, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is BIO-B's free cash flow?
Bio-Rad Laboratories, Inc..'s operating cash flow is $532.2M, with capital expenditures of $157.6M. FCF margin is 14.5%.
How does BIO-B compare to other Industrial stocks?
Vs Industrial sector averages: Net margin 29.4% (avg: 10%), ROE 10.2% (avg: 15%), current ratio 5.62 (avg: 1.8).